Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.

The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . Shareholders who purchased shares of MRK ...

For example, the Merck KGaA (ETR:MRK) share price is up 39% in the last five years, slightly above the market return. In comparison, the share price is down 13% in a year. So let's assess the ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...